These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24118636)

  • 21. Immunity against hepatitis E virus infection: Implications for therapy and vaccine development.
    Hakim MS; Ikram A; Zhou J; Wang W; Peppelenbosch MP; Pan Q
    Rev Med Virol; 2018 Mar; 28(2):. PubMed ID: 29272060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride: An immune-enhancing adjuvant for hepatitis E virus recombinant polypeptide vaccine in mice.
    Tao W; Zheng HQ; Fu T; He ZJ; Hong Y
    Hum Vaccin Immunother; 2017 Aug; 13(8):1818-1822. PubMed ID: 28604244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity.
    Zhang J; Li SW; Wu T; Zhao Q; Ng MH; Xia NS
    Rev Med Virol; 2012 Sep; 22(5):339-49. PubMed ID: 22645002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice.
    Deshmukh TM; Lole KS; Tripathy AS; Arankalle VA
    Vaccine; 2007 May; 25(22):4350-60. PubMed ID: 17459540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
    Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
    Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hepatitis E virus (HEV) zoonotic transmission: protection of rabbits against HEV challenge following immunization with HEV 239 vaccine.
    Liu P; Du Rj; Wang L; Han J; Liu L; Zhang Yl; Xia Jk; Lu Fm; Zhuang H
    PLoS One; 2014; 9(1):e87600. PubMed ID: 24498149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis E vaccine: why wait?
    Lancet; 2010 Sep; 376(9744):845. PubMed ID: 20833284
    [No Abstract]   [Full Text] [Related]  

  • 28. Toward the development of a hepatitis E vaccine.
    Kamili S
    Virus Res; 2011 Oct; 161(1):93-100. PubMed ID: 21620908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.
    Zhang M; Emerson SU; Nguyen H; Engle R; Govindarajan S; Blackwelder WC; Gerin J; Purcell RH
    Vaccine; 2002 Sep; 20(27-28):3285-91. PubMed ID: 12213398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods.
    Yin X; Wang X; Zhang Z; Li Y; Lin Z; Pan H; Gu Y; Li S; Zhang J; Xia N; Zhao Q
    J Pharm Biomed Anal; 2020 Jan; 177():112880. PubMed ID: 31546137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization.
    Yang S; Wang C; Fang X; Zhai L; Dong C; Ding L; Meng J; Wang L
    Virus Res; 2010 Aug; 151(2):162-9. PubMed ID: 20451569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine.
    Zhang J; Liu CB; Li RC; Li YM; Zheng YJ; Li YP; Luo D; Pan BB; Nong Y; Ge SX; Xiong JH; Shih JW; Ng MH; Xia NS
    Vaccine; 2009 Mar; 27(12):1869-74. PubMed ID: 19168109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus.
    Mazalovska M; Kouokam JC
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32751441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccination of rhesus monkeys with recombinant antigen fragments and protection from hepatitis E virus infection].
    Ma YB; Xie TH; Zhang GM; Li CH; Dai XJ; Dai CB; Sun MS; Lu J; Bi SL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Dec; 24(6):592-5. PubMed ID: 12905686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
    Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
    Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral immunization with recombinant hepatitis E virus antigen displayed on the Lactococcus lactis surface enhances ORF2-specific mucosal and systemic immune responses in mice.
    Gao S; Li D; Liu Y; Zha E; Zhou T; Yue X
    Int Immunopharmacol; 2015 Jan; 24(1):140-5. PubMed ID: 25445956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis E vaccine: WHO position paper, May 2015.
    Wkly Epidemiol Rec; 2015 May; 90(18):185-200. PubMed ID: 25935931
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine.
    Cao YF; Tao H; Hu YM; Shi CB; Wu X; Liang Q; Chi CP; Li L; Liang ZL; Meng JH; Zhu FC; Liu ZH; Wang XP
    Vaccine; 2017 Sep; 35(37):5073-5080. PubMed ID: 28803715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.
    Dong C; Dai X; Meng JH
    Vaccine; 2007 Feb; 25(9):1662-8. PubMed ID: 17156900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.
    Zhao Q; Zhang J; Wu T; Li SW; Ng MH; Xia NS; Shih JW
    J Gastroenterol; 2013 Feb; 48(2):159-68. PubMed ID: 23149436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.